vs

Side-by-side financial comparison of NPK International Inc. (NPKI) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

NPK International Inc. is the larger business by last-quarter revenue ($75.2M vs $69.8M, roughly 1.1× RIGEL PHARMACEUTICALS INC). On growth, NPK International Inc. posted the faster year-over-year revenue change (30.7% vs 21.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 23.9%).

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

NPKI vs RIGL — Head-to-Head

Bigger by revenue
NPKI
NPKI
1.1× larger
NPKI
$75.2M
$69.8M
RIGL
Growing faster (revenue YoY)
NPKI
NPKI
+9.5% gap
NPKI
30.7%
21.2%
RIGL
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
23.9%
NPKI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NPKI
NPKI
RIGL
RIGL
Revenue
$75.2M
$69.8M
Net Profit
$268.1M
Gross Margin
37.7%
91.5%
Operating Margin
16.7%
33.2%
Net Margin
384.0%
Revenue YoY
30.7%
21.2%
Net Profit YoY
1769.2%
EPS (diluted)
$0.17
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NPKI
NPKI
RIGL
RIGL
Q4 25
$75.2M
$69.8M
Q3 25
$68.8M
$69.5M
Q2 25
$68.2M
$101.7M
Q1 25
$64.8M
$53.3M
Q4 24
$57.5M
$57.6M
Q3 24
$44.2M
$55.3M
Q2 24
$66.8M
$36.8M
Q1 24
$49.0M
$29.5M
Net Profit
NPKI
NPKI
RIGL
RIGL
Q4 25
$268.1M
Q3 25
$5.7M
$27.9M
Q2 25
$8.7M
$59.6M
Q1 25
$10.0M
$11.4M
Q4 24
$14.3M
Q3 24
$-174.3M
$12.4M
Q2 24
$8.0M
$-1.0M
Q1 24
$7.3M
$-8.2M
Gross Margin
NPKI
NPKI
RIGL
RIGL
Q4 25
37.7%
91.5%
Q3 25
31.9%
93.2%
Q2 25
36.9%
95.6%
Q1 25
39.0%
91.7%
Q4 24
39.2%
89.9%
Q3 24
27.5%
85.5%
Q2 24
37.2%
92.4%
Q1 24
36.0%
93.1%
Operating Margin
NPKI
NPKI
RIGL
RIGL
Q4 25
16.7%
33.2%
Q3 25
13.2%
40.9%
Q2 25
17.0%
60.1%
Q1 25
20.9%
23.9%
Q4 24
20.2%
28.9%
Q3 24
2.8%
25.4%
Q2 24
18.7%
1.2%
Q1 24
14.2%
-23.6%
Net Margin
NPKI
NPKI
RIGL
RIGL
Q4 25
384.0%
Q3 25
8.2%
40.2%
Q2 25
12.7%
58.6%
Q1 25
15.4%
21.5%
Q4 24
24.9%
Q3 24
-394.3%
22.5%
Q2 24
12.0%
-2.8%
Q1 24
14.9%
-27.9%
EPS (diluted)
NPKI
NPKI
RIGL
RIGL
Q4 25
$0.17
$14.11
Q3 25
$0.07
$1.46
Q2 25
$0.10
$3.28
Q1 25
$0.11
$0.63
Q4 24
$0.10
$0.82
Q3 24
$-1.99
$0.70
Q2 24
$0.09
$-0.06
Q1 24
$0.08
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NPKI
NPKI
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$5.1M
$155.0M
Total DebtLower is stronger
$16.9M
$52.5M
Stockholders' EquityBook value
$351.2M
$391.5M
Total Assets
$441.8M
$513.6M
Debt / EquityLower = less leverage
0.05×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NPKI
NPKI
RIGL
RIGL
Q4 25
$5.1M
$155.0M
Q3 25
$35.6M
$137.1M
Q2 25
$26.0M
$108.4M
Q1 25
$20.8M
$77.1M
Q4 24
$17.8M
$77.3M
Q3 24
$42.9M
$61.1M
Q2 24
$35.1M
$49.1M
Q1 24
$37.7M
$49.5M
Total Debt
NPKI
NPKI
RIGL
RIGL
Q4 25
$16.9M
$52.5M
Q3 25
$9.5M
$60.0M
Q2 25
$9.3M
$60.0M
Q1 25
$8.1M
$60.0M
Q4 24
$7.7M
$60.0M
Q3 24
$14.0M
$60.0M
Q2 24
$58.0M
$60.0M
Q1 24
$77.4M
$60.0M
Stockholders' Equity
NPKI
NPKI
RIGL
RIGL
Q4 25
$351.2M
$391.5M
Q3 25
$333.9M
$117.6M
Q2 25
$328.8M
$81.9M
Q1 25
$326.9M
$18.6M
Q4 24
$326.5M
$3.3M
Q3 24
$316.5M
$-14.6M
Q2 24
$426.6M
$-29.9M
Q1 24
$421.6M
$-31.7M
Total Assets
NPKI
NPKI
RIGL
RIGL
Q4 25
$441.8M
$513.6M
Q3 25
$404.5M
$242.5M
Q2 25
$393.7M
$206.7M
Q1 25
$390.0M
$176.0M
Q4 24
$393.7M
$164.0M
Q3 24
$389.6M
$139.4M
Q2 24
$624.8M
$128.4M
Q1 24
$640.8M
$126.5M
Debt / Equity
NPKI
NPKI
RIGL
RIGL
Q4 25
0.05×
0.13×
Q3 25
0.03×
0.51×
Q2 25
0.03×
0.73×
Q1 25
0.02×
3.23×
Q4 24
0.02×
18.25×
Q3 24
0.04×
Q2 24
0.14×
Q1 24
0.18×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NPKI
NPKI
RIGL
RIGL
Operating Cash FlowLast quarter
$18.0M
$22.0M
Free Cash FlowOCF − Capex
$5.8M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
16.3%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$26.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NPKI
NPKI
RIGL
RIGL
Q4 25
$18.0M
$22.0M
Q3 25
$24.7M
$24.0M
Q2 25
$21.4M
$30.5M
Q1 25
$8.8M
$-893.0K
Q4 24
$-4.1M
$14.5M
Q3 24
$2.8M
$21.7M
Q2 24
$27.6M
$302.0K
Q1 24
$11.9M
$-5.0M
Free Cash Flow
NPKI
NPKI
RIGL
RIGL
Q4 25
$5.8M
Q3 25
$12.0M
Q2 25
$9.7M
Q1 25
$-1.2M
Q4 24
$-17.7M
Q3 24
$-6.7M
Q2 24
$21.0M
Q1 24
$-1.9M
FCF Margin
NPKI
NPKI
RIGL
RIGL
Q4 25
7.6%
Q3 25
17.4%
Q2 25
14.3%
Q1 25
-1.8%
Q4 24
-30.8%
Q3 24
-15.2%
Q2 24
31.4%
Q1 24
-3.9%
Capex Intensity
NPKI
NPKI
RIGL
RIGL
Q4 25
16.3%
Q3 25
18.5%
Q2 25
17.1%
Q1 25
15.5%
Q4 24
23.6%
Q3 24
21.4%
Q2 24
9.9%
Q1 24
28.3%
Cash Conversion
NPKI
NPKI
RIGL
RIGL
Q4 25
0.08×
Q3 25
4.37×
0.86×
Q2 25
2.47×
0.51×
Q1 25
0.88×
-0.08×
Q4 24
1.01×
Q3 24
1.75×
Q2 24
3.43×
Q1 24
1.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NPKI
NPKI

Rental Revenue$34.8M46%
Products$25.5M34%
Services$14.9M20%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons